Navigation Links
Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
Date:8/21/2008

SAN FRANCISCO, Aug. 21 /PRNewswire-FirstCall/ -- Medizone International, Inc. (Pink Sheets: MZEI) announces the appointment of Michael E. Shannon, M.A., M.Sc., M.D. to its Board of Directors. Dr. Shannon received his medical degree from Queen's University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years. He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments, he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years. In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special assignment with the Canadian Federal Government Auditor General's office. His assignment was to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament on that project was completed in November 2004. Dr. Shannon recently worked on a special project assignment as Senior Medical Advisor to the Canadian Public Health Agency. His assignment was to review and help rebuild the Canadian Public Health Agency's Emergency Medical Response Capacity. His work in that regard with the Canadian government was completed the end of July this year.

Internationally respected for his expertise, Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based), research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University.

Medizone's Chairman and CEO, Edwin Marshall commented; "On behalf of the members of the board and all of the Company's shareholders, we welcome Dr. Shannon to our Board of Directors. The wisdom and expertise Dr. Shannon brings to Medizone is unparalleled in the history of our company. I consider him a remarkable man and feel honored to be able to refer to him as a professional associate. This appointment signals an immense step forward in the reorganization of Medizone International.

Medizone International, Inc., is a research and development stage company engaged in the development of patented and unpatented technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
2. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
3. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
4. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
5. Chindex International, Inc. Quantifies Fourth Quarter Charges
6. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
7. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
8. MINRAD International, Inc. to Discuss 2008 First Quarter Financial Results on Tuesday, May 13, 2008
9. MINRAD International, Inc. Announces $40.0 Million Private Placement
10. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
11. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
Breaking Biology Technology:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):